Navigation Links
Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
Date:8/20/2007

hilarating!" commented Mr. Rafferty. "My first task is to build a formidable and experienced sales team as quickly as possible."

"I am delighted to be joining the Pathway Medical team at such an exciting time. We are well-positioned for terrific growth as we commercialize the Pathway PV Atherectomy System," he said.

About Pathway Medical Technologies, Inc.

Pathway Medical Technologies, Inc. was founded to develop, manufacture and market medical devices for the treatment of arterial disease. The company's initial focus is treating peripheral arterial disease (PAD) more quickly, safely and effectively than existing technologies. An estimated 14 million people are afflicted by PAD in the United States, and that number is projected to grow to over 20 million during the next 10 years. The company's Pathway PV System allows for a minimally invasive procedure designed to restore circulation in the peripheral arteries by removing both hard and soft diseased tissue.

Nine months ago, the company passed a major milestone when it received a $25 million Series B round of financing from five venture capital investors.

Company Contact:

Thomas J. Clement

CEO/President

(425)636-4122

clementt@pathwaymedical.com


'/>"/>
SOURCE Pathway Medical Technologies, Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related biology technology :

1. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. In Vivo Signal Transduction Pathway Reporting Systems
4. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
5. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
6. Medical College receives $377K to study brain disease
7. Barriers will not stop convergence of medical technologies
8. Medical College team creates website for tracking flu
9. Biomedical engineering conference invites manufacturers
10. Visions: Wade offers straight talk on e-medical records
11. Merge unveils updated medical imaging software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, ... for the treatment of chronic pain, announced the results ... "This was a transformational year in Relmada,s ... future for our company," said Sergio Traversa , ... we have executed on key financial, human resource and ...
(Date:12/17/2014)... USA (PRWEB) December 16, 2014 ... manager at Philipps- Universität Marburg’s Department of Physics, ... photonics, in the newly released SPIE Women ... never be too shy to ask questions.” , ... technology, engineering, and mathematics) occupations ranging from university ...
(Date:12/17/2014)... 17, 2014 Once more, EMAAR ... larger packaged waste water treatment plant to phase one ... City (KAEC). Two years ago Bioshaft successfully supplied and ... serving two residential towers with an occupancy of 900 ... quarter million gallons per day and was signed on ...
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
... SAN FRANCISCO, Calif., Dec. 9 Proteolix, Inc. ... lead,product, carfilzomib, has single-agent activity and promotes durable ... Carfilzomib is the,first in a new class ... the treatment of hematologic malignancies and solid tumors. ...
... Dec. 9 /PRNewswire/ - Interface Biologics Inc. - a ... implantable medical devices - is announcing that it has ... were existing investors Covington Capital, VG Partners and BDC ... Covington Capital is joining the Board of Directors and ...
... Soliris(R) (eculizumab),a terminal complement inhibitor developed by Alexion ... investigators to reduce blood measures,associated with undiagnosed blood clots ... A separate study found that ... (PAH) in patients with paroxysmal nocturnal,hemoglobinuria (PNH), according to ...
Cached Biology Technology:Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology 2Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology 3Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology 4Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology 5Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology 6Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer 2Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 2Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 3Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 4Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 5Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 6Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 7Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 8
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... Critical Data with MobileCop(R) ... ... Inc.,(OTC Bulletin Board: BKYI), a leader in finger-based biometric,identification and wireless ... (MD) Police Department ("BPD"),for additional licenses of BIO-key,s MobileCop software for ...
... Priscilla P. Nelson, of West Orange, received the Kenneth ... Sciences on May 5th for promoting unity among engineering ... at NJIT ( www.njit.edu ) coupled with earlier leadership ... Nelson arrived at NJIT in 2005 after spending more ...
... known as a working copy of the DNA sequence of ... genes instructions to the cell, which manufactures proteins according to ... increasingly realized that many RNA snippets -- so-called small RNAs ... some cases, how much protein. Theyve also found that some ...
Cached Biology News:BIO-key(R) Receives $335,000 Contract Award From Baltimore Police 2BIO-key(R) Receives $335,000 Contract Award From Baltimore Police 3NJIT Provost Priscilla P. Nelson honored at National Academy of Engineering 2Scientists discover small RNAs that regulate gene expression and protect the genome 2Scientists discover small RNAs that regulate gene expression and protect the genome 3
Peptide-affinity Purified Polyclonal Antibody to Purinergic Receptor P2Y12...
Peptide-affinity Purified Polyclonal Antibody to SMAD7 Peptide with sequence SSCPCWLEVIFNSR, from C Terminus of the protein sequence according to NP_005895....
Mouse monoclonal [b/e4 (9.20)] to Cytochrome P450 2B1 + 2B2 ( Abpromise for all tested applications)....
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Biology Products: